Phase I and II clinical trials of MAGEA3 peptide-based vaccines in patients with completely resected stage IB-II NSCLC demonstrated safety and showed a trend toward improved disease-free interval (DFI) and disease-free survival (DFS) [119,120]. Here, MAGEA3 is linked to non-small cell lung carcinoma.